Immunic Inc. (NASDAQ: IMUX)
$1.44
-0.0400 ( -2.70% ) 170.7K
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
Market Data
Open
$1.44
Previous close
$1.48
Volume
170.7K
Market cap
$130.62M
Day range
$1.42 - $1.51
52 week range
$0.95 - $2.78
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Jul 12, 2024 |
3 | Insider transactions | 1 | Jul 12, 2024 |
8-k | 8K-related | 15 | Jul 09, 2024 |
8-k | 8K-related | 13 | Jun 13, 2024 |
4 | Insider transactions | 1 | Jun 12, 2024 |
4 | Insider transactions | 1 | Jun 12, 2024 |
4 | Insider transactions | 1 | Jun 12, 2024 |
4 | Insider transactions | 1 | Jun 12, 2024 |
4 | Insider transactions | 1 | Jun 12, 2024 |
8-k | 8K-related | 33 | May 08, 2024 |